Home > News > Thyroid Nodules – Management Dilemmas and Theraputic Considerations
Thyroid Disorders
Read Time: 3 mins

Thyroid Nodules – Management Dilemmas and Theraputic Considerations

Published Online: June 6th 2011 US Endocrinology, 2005;(1):68-70 DOI: http://doi.org/10.17925/USE.2005.00.01.68
Authors: M Regina Castro
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Thyroid nodules are very common in clinical practice, with an overall prevalence that varies from 4% by palpation to 67% by ultrasonography. The annual incidence by palpation has been estimated at 0.09% by the Framingham study,1 which translates into approximately 300,000 new nodules in the US in 2005. Despite their high frequency, only a small fraction (~5%) of thyroid nodules harbor cancer. Because only malignant or large, symptomatic nodules will require surgical excision, a systematic approach to their evaluation is important to avoid unnecessary surgery. Certain aspects in the evaluation and management of thyroid nodules remain controversial or represent clinical dilemmas.

Article:

‘ Non – diagnostic ’ Smear

‘ Non – diagnostic ’ Smear
Fine needle aspiration (FNA) biopsy is the most costeffective and accurate method of distinguishing benign from malignant thyroid nodules. This procedure has led to a substantial reduction of unnecessary surgeries, while doubling or tripling the malignancy yield at thyroidectomy. Despite its overall excellent accuracy, approximately 15% of all specimens will be classified as ‘non-diagnostic’ or ‘insufficient’, a diagnosis that poses a management dilemma. Repeat aspiration, preferably under ultrasound guidance, can significantly reduce the rate of non-diagnostic smears. However, when repeat aspiration fails to provide an adequate specimen, the clinician must decide whether to follow the patient clinically or refer for surgical excision. Certain clinical features (history of head or neck irradiation, rapid nodule growth, a hard nodule with fixation to surrounding tissues, compressive symptoms such as dysphagia or persistent hoarseness) increase the likelihood of malignancy in a nodule and may be considered an indication for surgery. However, many patients who lack such clinical features are often found to have thyroid cancer on subsequent evaluation. It is important to recognize that ‘nondiagnostic’ is not synonymous with benign disease, as shown in a study where a 9% incidence of malignancy and a 52% rate of neoplasia was seen after surgical excision of nodules with repeatedly non-diagnostic cytopathology.2 In the presence of ‘high-risk’ clinical features, surgical excision should be considered to definitively exclude malignancy, while observation and re-evaluation in six to 12 months may be appropriate for low-risk patients. ‘ Suspicious ’ or ‘ Indeterminate ’ Cytology
The finding of ‘indeterminate’ or ‘suspicious’ cytologyon FNA biopsy of thyroid nodules is one of the most challenging diagnostic dilemmas for the endocrinologist, and the best management strategy remains controversial. This category includes cytologic findings commonly referred to as ‘follicular neoplasms’ that include hyperplastic nodules, follicular adenomas and carcinomas, and follicular variants of papillary carcinoma.3 The microscopic distinction is difficult, leading most clinicians to recommend surgical excision for a definitive diagnosis. Due to the fact that only 15% to 20% of these lesions will ultimately be found to represent cancer,4,5 up to 85% of patients in this subgroup may undergo unnecessary surgery, with its attendant high cost and potential morbidity. Many studies have attempted to determine factors predictive of malignancy in patients with cytologic findings ‘suspicious for follicular neoplasm’.6,7 Although certain clinical findings (large nodule diameter, fixation to surrounding tissue,male gender, and younger age of the patient) were associated with increased risk of malignancy in some studies,6,7 others found that no cytological,3 clinical, scintigraphic, or ultrasonographic characteristics were predictive of malignancy.8 Other techniques, such as the use of electron microscopy, flow cytometry, and several genetic markers, have been evaluated, but have not improved diagnostic reliability. However, two immunohistochemical markers (HBME- 1 and galectin-3) have shown promise in their ability to predict malignancy and their potential for ease of use in any surgical or cytopathology laboratory, in academic or community settings.9,10 Bartolazzi et al. conducted a retrospective analysis of 618 tissue specimens and 165 cell blocks, as well as a prospective analysis of 226 ultrasound guided (UG)-FNA specimens.9 In the retrospective review of their surgical specimens, 94% of 311 malignant cases stained positive for galectin-3. Less than 3% of papillary carcinomas failed to express this marker.Thirty-seven (93%) minimally invasive follicular thyroid carcinomas were positive for galectin-3, and this marker was not expressed in any case of nodular hyperplasia or thyroiditis. More importantly, the prospective analysis focussed on 90 cases in which conventional cytology was inconclusive. In these cases, the addition of galectin-3 allowed the correct identification of all malignancies, including five minimally invasive follicular carcinomas.

Evaluation of the Patient with Multinodular Goiter
The evaluation of a patient with a palpable solitary nodule is generally straightforward and will usually include FNA biopsy with or without ultrasound guidance. It is important to recognize that in up to 48% of patients with a clinically palpable solitary nodule, ultrasonography will often demonstrate the presence of one or more additional nodules.11 The evaluation and management of patients with multinodular goiters (MNG) represents a much more difficult problem in the clinical setting. It had been suggested that, in the setting of multi-nodularity, a dominant palpable thyroid nodule is most often benign,12 but a study by Belfiore et al.13 found that the frequency of thyroid cancer in patients with a solitary nodule (4.7%) does not differ from that in patients with a non-toxic MNG (4.1%). Because no single clinical or ultrasonographic feature has been found to reliably confirm or exclude the presence of malignancy, selection of the nodule(s) that will require biopsy needs careful consideration. It is generally recommended that in the setting of a multinodular goiter, the dominant nodule should be biopsied. However, certain ultrasonographic features of thyroid nodules, such as hypoechogenicity, the presence of microcalcifications, increased vascular flow, or irregular borders, are associated with increased risk of malignancy14 and, when present, should help the clinical in selecting the target of the FNA biopsy (see Figures 1 and 2). In the absence of these features malignancy cannot definitively be excluded, therefore patients with MNG should be followed with periodic neck

examination and ultrasonography and a repeat biopsy should be considered if significant growth of a nodule is noted or other worrisome clinical (persistent hoarseness, dysphagia, adenopathy, etc.) or sonographic features develop on follow-up.

Article Information:

References

  1. Vander J B, Gaston E A, Dawber T R, “The significance of nontoxic thyroid nodules: Final report of a 15 year study of the incidence of thyroid malignancy”, Ann. Intern. Med. (1968);69: pp. 537–540.
  2. McHenry C R,Walfish P G, Rosen I B, “Non-diagnostic fine-needle aspiration biopsy: A dilemma in management of nodular thyroid disease”, Am. Surg. (1998);59: pp. 415–419.
  3. Greaves T S, Olvera M, Florentine B D et al.,“Follicular lesions of thyroid: a 5-year fine-needle aspiration experience”, Cancer (2000);90: pp. 335–341.
  4. Castro M R, Gharib H, “Continuing controversies in the management of thyroid nodules”, Ann. Intern. Med. (2005);142: pp. 926–931.
  5. Gharib H, Goellner J R, Zinsmeister A R et al.,“Fine needle aspiration biopsy of the thyroid.The problem of suspicious cytologic findings”, Ann. Intern. Med. (1984);101: pp. 25–28.
  6. Tuttle R M, Lemar H, Burch H B, “Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration”, Thyroid (1998);8: pp. 377–383.
  7. Schlinkert R T,Van Heerden J A, Goellner J R et al.,“Factors that predict malignant thyroid lesions when fine-needle aspiration is “suspicious for follicular neoplasm”, Mayo Clin. Proc. (1997);72: pp. 913–916.
  8. Cersosimo E, Gharib H, Suman V J et al.,“‘Suspicious’ thyroid cytologic findings: outcome in patients without immediate surgical treatment”, Mayo Clin. Proc. (1993);68: pp. 343–348.
  9. Bartolazzi A, Gasbarri A, Papotti M et al.,“Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions”, Lancet (2001);357: pp. 1,644–1,650.
  10. Miettinen M, Karkkainen P, “Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours”, Virchows Arch. (1996);429: pp. 213–219.
  11. Tan G H, Gharib H, Reading C C, “Solitary thyroid nodule: comparison between palpation and ultrasonography”, Arch. Intern. Med. (1995);155: pp. 2,418–2,423.
  12. Simeone J F, Daniels G H, Mueller P R et al.,“High resolution real-time sonography of the thyroid” Radiology (1982);145: pp. 431–435.
  13. Belfiore A, La Rosa G L, La Porta G A et al., “Cancer risk in patients with cold thyroid nodules: Relevance of iodine intake, sex, age and multinodularity”, Am. J. Med. (1992);93: p. 393.
  14. Papini E, Guglielmi R, Bianchini A et al., “Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features”, J. Clin. Endocrinol. Metab. (2002);87: pp. 1,941–1,946.
  15. Celani M, Mariani M, Mariani G, “On the usefulness of levothyroxine suppressive therapy int he medical treatment of benign, solitary, solid or predominantly solid, thyroid nodules”, Acta. Endocrinol. (1990);123: pp. 603–608.
  16. La Rosa G, Lupo L, Giuffrida D et al.,“Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid”, Ann. Intern. Med. (1995);122: p. 1–8.
  17. Zelmanovitz F, Genro S, Gross J, “Suppressive therapy with levothyroxine for solitary thyroid nodules:A double-blind controlled clinical study and cumulative meta-analyses”, J. Clin. Endocrinol. Metab. (1998);83: pp. 3,881–3,885.
  18. Wemeau J L, Caron P, Schvartz C et al.,“Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group”, J. Clin. Endocrinol. Metab. (2002);87: pp. 4,928–4,934.
  19. Gharib H, James E M, Charboneau J W, et al., “Suppressive therapy with levothyroxine for solitary thyroid nodules.A doubleblind controlled clinical study”, N. Engl. J. Med. (1987);317: pp. 70–75.
  20. Larijani B, Pajouhi M, Bastanhagh M et al., “Evaluation of suppressive therapy for cold thyroid nodules with levothyroxine: Double blind placebo-controlled clinical trial”, Endocr. Pract. (1999);5: pp. 251–256.
  21. Castro M R, Caraballo P J, Morris J C,“Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis”, J. Clin. Endocrinol. Metab. (2002);87: pp. 4,154–4,159.
  22. Sawin C T, Geller A,Wolf P A et al.,“Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons”, N. Engl. J. Med. (1994);331: pp. 1,249–1,252.
  23. Faber J, Galloe A M,“Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a metaanalysis”, Eur. J. Endocrinol. (1994);130: pp. 350–356.
  24. Koc M, Ersoz H O, Akpinar I et al.,“Effect of low- and high-dose levothyroxine on thyroid nodule volume: a crossover placebocontrolled trial”, Clin. Endocrinol. (Oxf), (2002);57: pp. 621–628.
  25. Valcavi R, Frasoldati A, “Ultrasound-guided percutaneous ethanol injection therapy in thyroid cystic nodules”, Endocr. Pract. (2004);10: pp. 269–275.
  26. Ferris J V,“Serial ethanol ablation of multiple hepatic cysts as an alternative to liver transplantation”, AJR Am. J. Roentgenol. (2003);180: pp. 472–474.
  27. Bean W J, Rodan B A,“Hepatic cysts: treatment with alcohol”, AJR Am. J. Roentgenol. (1985);144: pp. 237–241.
  28. Verges B L, Cercueil J P, Jacob D et al.,“Results of ultrasonically guided percutaneous ethanol injection into parathyroid adenomas in primary hyperparathyroidism”, Acta. Endocrinol. (Copenh), (1993);129: pp. 381–387.
  29. Lippi F, Ferrari C, Manetti L et al.,“Treatment of solitary autonomous thyroid nodules by percutaneous ethanol injection: results of an Italian multicenter study.The Multicenter Study Group”, J. Clin. Endocrinol. Metab. (1996). 81: p. 3261-3264.
  30. Monzani F, Caraccio N, Goletti O et al., “Five-year follow-up of percutaneous ethanol injection for the treatment of hyperfunctioning thyroid nodules: a study of 117 patients”, Clin. Endocrinol. (Oxf), (1997);46: pp. 9–15.
  31. Zingrillo M, Collura D, Ghiggi M R et al., “Treatment of large cold benign thyroid nodules not eligible for surgery with percutaneous ethanol injection”, J. Clin. Endocrinol. Metab. (1998);83: pp. 3,905–3,907.
  32. Bennedbaek F N, Hegedus L,“Percutaneous ethanol injection therapy in benign solitary solid cold thyroid nodules: a randomized trial comparing one injection with three injections”, Thyroid (1999);9: pp. 225–233.
  33. De Los Santos E T, Keyhani-Rofagha S, Cunningham J J et al., “Cystic thyroid nodules:The dilemma of malignant lesions”, Arch. Intern. Med. (1990);150: pp. 1,422–1,427.
  34. Alexander E K, Heering J P, Benson C B et al.,“Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules”, J. Clin. Endocrinol. Metab. (2002);87: pp. 4,924–4,927.
  35. Bennedbaek F N, Hegedus L,“Treatment of recurrent thyroid cysts with ethanol: a randomized double-blind controlled trial”, J. Clin. Endocrinol. Metab. (2003);88: pp. 5,773–5,777.
  36. Verde G, Papini E, Pacella C M et al., “Ultrasound guided percutaneous ethanol injection in the treatment of cystic thyroid nodules”, Clin. Endocrinol. (Oxf), (1994);41: pp. 719–724.
  37. Zingrillo M,Torlontano M, Chiarella R et al., “Percutaneous ethanol injection may be a definitive treatment for symptomatic thyroid cystic nodules not treatable by surgery: five-year follow-up study”, Thyroid (1999);9: pp. 763–767.
  38. Jayaram G, Kaur A, “Cystic thyroid nodules harboring malignancy: a problem in fine needle aspiration cytodiagnosis”, Acta. Cytol. (1989);33: pp. 941–942.
  39. Pacella C M, Bizzarri G, Magnolfi F et al., “Laser thermal ablation in the treatment of small hepatocellular carcinoma: results in 74 patients”, Radiology (2001);221: pp. 712–720.
  40. Pacella C M, Bizzarri G, Cecconi P et al.,“Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization”, Radiology (2001);219: pp. 669–678.
  41. Dick E A, Joarder R, de Jode M et al., “MR-guided laser thermal ablation of primary and secondary liver tumours”, Clin. Radiol. (2003);58: pp. 112–120.
  42. Dick E A, Joarder R, De Jode M G et al.,“Magnetic resonance imaging-guided laser thermal ablation of renal tumours”, BJU Int. (2002);90: pp. 814–822.
  43. Dossing H, Bennedbaek F N, Hegedus L,“Ultrasound-guided interstitial laser photocoagulation of an autonomous thyroid nodule: the introduction of a novel alternative”, Thyroid (2003);13: pp. 885–888.
  44. Spiezia S, Vitale G, Di Somma C et al., “Ultrasound-guided laser thermal ablation in the treatment of autonomous hyperfunctioning thyroid nodules and compressive nontoxic nodular goiter”, Thyroid (2003);13: pp. 941–947.
  45. Pacella C M, Bizzarri G, Guglielmi R et al., “Thyroid tissue: US-guided percutaneous interstitial laser ablation-a feasibility study”, Radiology (2000);217: pp. 673–677.
  46. Papini E, Guglielmi R, Bizzarri G et al., “Ultrasound-guided laser thermal ablation for treatment of benign thyroid nodules”, Endocr. Pract. (2004);10: pp. 276–283.

Further Resources

Share this Article
Related Content In Thyroid Disorders
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72